Citizens Jmp Raises argenex (NASDAQ:ARGX) Price Target to $944.00

by · The Cerbat Gem

argenex (NASDAQ:ARGX – Get Free Report) had its price target upped by research analysts at Citizens Jmp from $925.00 to $944.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s target price would indicate a potential upside of 22.35% from the company’s previous close.

A number of other equities research analysts have also recently commented on ARGX. Piper Sandler increased their target price on argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Truist Financial upped their price target on shares of argenex from $950.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Evercore raised their price objective on shares of argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Royal Bank Of Canada lifted their target price on shares of argenex from $860.00 to $925.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Finally, Robert W. Baird increased their price target on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,005.06.

Check Out Our Latest Stock Report on ARGX

argenex Price Performance

Shares of argenex stock opened at $771.53 on Friday. argenex has a 1 year low of $510.05 and a 1 year high of $934.62. The firm has a market cap of $47.74 billion, a price-to-earnings ratio of 33.13, a PEG ratio of 0.71 and a beta of 0.37. The company has a 50-day moving average of $828.13 and a 200 day moving average of $809.87.

argenex (NASDAQ:ARGX – Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.05 by $1.97. The business had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.30 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. On average, equities analysts anticipate that argenex will post 3.13 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ARGX. Abound Wealth Management increased its stake in shares of argenex by 3,200.0% in the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after purchasing an additional 32 shares in the last quarter. Sound Income Strategies LLC bought a new stake in argenex during the fourth quarter valued at about $28,000. Ameriflex Group Inc. purchased a new stake in argenex in the third quarter worth about $32,000. Sunbelt Securities Inc. bought a new position in shares of argenex in the third quarter worth about $36,000. Finally, Aventura Private Wealth LLC bought a new position in shares of argenex in the fourth quarter worth about $38,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

  • Positive Sentiment: Q4 earnings and full‑year results topped expectations — $8.02 EPS vs. $6.05 consensus and $1.32B Q4 product sales; FY2025 product net sales of $4.2B (≈90% YoY growth). This confirms strong current cashflow and execution that investors reward. Full Year Results
  • Positive Sentiment: Positive topline Phase 3 ADAPT OCULUS results for VYVGART in ocular myasthenia gravis (met primary endpoint, p=0.012) — supports planned sBLA to expand the U.S. label, which can drive additional addressable market and revenue growth. ADAPT OCULUS Press Release
  • Positive Sentiment: HC Wainwright raised its price target to $940 and maintained a buy rating — a bullish analyst view that reinforces upside expectations. Benzinga
  • Neutral Sentiment: Robert W. Baird nudged its target up slightly to $867 but kept a neutral rating — modestly constructive but not a strong buy signal. Benzinga
  • Neutral Sentiment: Coverage pieces and previews (e.g., Yahoo/MarketBeat/Benzinga earnings previews and call materials) provide detail for investors but largely reiterate the above catalysts and guidance. What To Expect (Yahoo) Earnings Transcript
  • Neutral Sentiment: Reported short‑interest data appears to show 0 shares (likely a data artifact) and provides no clear signal on investor positioning. Treat this as non‑informative until clarified.
  • Negative Sentiment: Guggenheim trimmed its price target from $1,160 to $1,120 (still a buy) — a cut that could temper some upside enthusiasm despite the high absolute target. Benzinga

About argenex

(Get Free Report)

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

Further Reading